Tuesday, 19 Mar 2019

You are here

CDC Top 15 Most Common Opioid Overdose Drugs

The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.

From 1999 through 2016, the age-adjusted rate of drug overdose deaths in the United States more than tripled from 6.1 per 100,000 to 19.8 per 100,000 according to the report.

The top 15 drugs were identified based on the number of drug overdose deaths per referent drug category. While the ranking changed from year to year, the top 10 drugs involved in overdose deaths remained consistent throughout the 6-year period. The top 10 drugs belonged to three drug classes:

  • Opioids: fentanyl, heroin, hydrocodone, methadone, morphine, and oxycodone
  • Benzodiazepines: alprazolam and diazepam
  • Stimulants: cocaine and methamphetamine 

In 2011, oxycodone ranked first, while heroin and fentanyl were ranked first during 2012 to 2015 and in 2016, respectively.

Cocaine consistently ranked second or third during the study period. The age-adjusted rate of drug overdose deaths involving heroin more than tripled from 2011 through 2016, as did the rate of drug overdose deaths involving methamphetamine.

Each year from 2013 to 2016, the rate of drug overdose deaths involving fentanyl and fentanyl analogs doubled (0.6, 1.3, 2.6, and 5.9 per 100,000 in 2013, 2014, 2015, and 2016, respectively).

This report shows that the most frequent drugs mentioned varied over time and by intent of death (i.e., unintentional drug overdose, suicide by drug overdose, and overdose death of undetermined intent). Results from the literal text analysis also confirm that many drug overdose deaths involve multiple drugs.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Best of 2018: The Safety of Paternal Exposure to DMARDs and Biologics

Pregnancy and drug safety is a complex issue, often with limited information about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

A systematic review examined the effect of disease modifying anti-rheumatic drugs (DMARDs) on male fertility and if peri-conception (within 3 months) paternal exposure was detrimental to fetal outcomes.

Best of 2018: Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

Trazodone High Risk of Falls and Fractures

The CMAJ (Canadian Medical Association Journal) has reported that trazadone use in the elderly may be associated with a risk of falls and major fractures. 

Using claims data from ICES, researchers compared 6588 seniors given trazadone to 2875 receiving another atypical antipsychotic.

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs. 

Low Short-Term Risks of NSAIDs in High Risk Patients

JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-37 days of exposure).